Showing results (1601-1610 of 4,521) with videos related to
Sort By:
Pageof 453
Future Oncology (London, England)|December 4, 2018
Necitumumab for the treatment of advanced non-small-cell lung cancerAsunción Díaz-Serrano, Ana Sánchez-Torre, Luis Paz-AresFuture Oncology (London, England)|December 15, 2018
Nilotinib in the treatment of chronic myeloid leukemiaTomasz Sacha, Giuseppe SaglioFuture Oncology (London, England)|December 22, 2018
HTX-019 via 2-min injection or 30-min infusion in healthy subjectsThomas Ottoboni, Michael Lauw, Mary Rose Keller, et al.Future Oncology (London, England)|November 28, 2018
An observational study on the clinical features of esophageal cancer followed by multiple primary cancersZhipeng Hu, Min Zhang, Zhiwei Wang, et al.Future Oncology (London, England)|January 24, 2020
Current and future role of fedratinib in the treatment of myelofibrosisMonica Ragheb, Claire N Harrison, Donal P McLornanFuture Oncology (London, England)|January 25, 2020
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patientSalvatora Tindara Miano, Edoardo Francini, Roberto Petrioli, et al.Future Oncology (London, England)|August 29, 2020
CD38 as an immunomodulator in cancerYanli Li, Rui Yang, Limo Chen, et al.Future Oncology (London, England)|October 30, 2019
Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapySarah S Mougalian, Bruce A Feinberg, Edward Wang, et al.Future Oncology (London, England)|March 3, 2018
ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trialClaudia M Gorcea, John Burthem, Eleni TholouliFuture Oncology (London, England)|February 14, 2019
FMO1 gene expression independently predicts favorable recurrence-free survival of classical papillary thyroid cancerJing Luo, Bowei Zhang, Likun Cui, et al.Pageof 453